Get the Stockscreener App
0.185
0.38%
0.0007
After Hours:
.18
-0.005
-2.70%
Carisma Therapeutics Inc stock is traded at $0.185, with a volume of 338.20K.
It is up +0.38% in the last 24 hours and down -15.10% over the past month.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
See More
Previous Close:
$0.1843
Open:
$0.1904
24h Volume:
338.20K
Relative Volume:
0.87
Market Cap:
$7.73M
Revenue:
$20.27M
Net Income/Loss:
$-63.80M
P/E Ratio:
-0.1217
EPS:
-1.52
Net Cash Flow:
$-68.35M
1W Performance:
+11.18%
1M Performance:
-15.10%
6M Performance:
-77.51%
1Y Performance:
-85.32%
1-Day Range:
$0.1803
$0.1926
1-Week Range:
$0.1639
$0.20
52-Week Range:
$0.1417
$1.90
Carisma Therapeutics Inc Stock (CARM) Company Profile
Name
Carisma Therapeutics Inc
Sector
Industry
Phone
(267) 491-6422
Address
3675 MARKET STREET, PHILADELPHIA
Compare CARM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CARM
Carisma Therapeutics Inc
|
0.185 | 6.95M | 20.27M | -63.80M | -68.35M | -1.52 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-10-24 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-11-24 | Initiated | BTIG Research | Buy |
| Oct-03-23 | Initiated | CapitalOne | Overweight |
| Jul-06-23 | Initiated | Evercore ISI | Outperform |
| May-31-23 | Upgrade | Jefferies | Hold → Buy |
| May-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-23 | Initiated | Robert W. Baird | Outperform |
View All
Carisma Therapeutics Inc Stock (CARM) Latest News
Carisma Therapeutics Inc (CARM): An Important Analyst Insights - Stocksregister
Carisma Therapeutics Inc (NASDAQ: CARM) Stock Sentiment: What’s Wall Street Saying? - Stocksregister
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
Carisma Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Average Recommendation of “Hold” by Brokerages - Defense World
Financial Metrics Unveiled: Carisma Therapeutics Inc (CARM)’s Key Ratios in the Spotlight - DWinneX
Carisma Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Carisma Therapeutics to Present at Upcoming Conferences - Seeking Alpha
Biopharma restructurings reflect strategy of short-term pain for long-term gains - BioWorld MedTech
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Average Rating of “Hold” by Analysts - Defense World
Sagimet Biosciences (NASDAQ:SGMT) and Carisma Therapeutics (NASDAQ:CARM) Head-To-Head Review - Defense World
Philly weekly roundup: Carisma Therapeutics layoffs; PPA's AI ticketing; HiveBio's first cohort - Technical.ly
Carisma Therapeutics Inc’s Market Journey: Closing Weak at 0.19, Down -0.26 - DWinneX
CARISMA THERAPEUTICS Earnings Preview: Recent $CARM Insider Trading, Hedge Fund Activity, and More - Nasdaq
Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan - MSN
Philly’s Carisma Therapeutics slashed its workforce to 6 from 46 for sale or wind down - MSN
Carisma Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance
Carisma Therapeutics (NASDAQ:CARM) Price Target Lowered to $1.00 at D. Boral Capital - Defense World
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Carisma Therapeutics to Present at AASLD 2024 on Liver Fibrosis Treatment - MSN
Carisma winds down operations, lays off 95% of remaining staff - Fierce Biotech
Penn spinout Carisma Therapeutics lays off 84% of its staff, explores possible sale - The Business Journals
Carisma Therapeutics Provides Corporate Updates - Citizen Tribune
Carisma Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Carisma Therapeutics Board Approves Revised Operating Plan; Reduces Workforce - MarketScreener
Carisma Therapeutics Inc. SEC 10-K Report - TradingView
Carisma Therapeutics (CARM) to Release Earnings on Monday - The AM Reporter
Carisma Therapeutics, Inc.'s (NASDAQ:CARM) Business And Shares Still Trailing The Industry - simplywall.st
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Rating of “Hold” from Analysts - Defense World
Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annua - GuruFocus.com
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Michael Klichinsky to Speak at H.C. Wainwright Cell Therapy Virtual Conference - MSN
Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 - Quantisnow
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Quantisnow
Carisma Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Conference - MSN
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference - Quantisnow
Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Carisma Therapeutics Inc Stock (CARM) Financials Data
Revenue
Net Income
Cash Flow
EPS
17.27%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):